STOCKS TELEGRAPH

Tag: CPHI

  • 3 Stocks Building Momentum Fast: Clearmind Medicine (CMND), China Pharma (CPHI), Cardiol Therapeutics (CRDL)

    3 Stocks Building Momentum Fast: Clearmind Medicine (CMND), China Pharma (CPHI), Cardiol Therapeutics (CRDL)

    The search for high-growth opportunities has led many investors to explore under-the-radar stocks that may be on the verge of significant breakthroughs. Particularly within the healthcare space, companies advancing novel therapies or addressing unmet medical needs are starting to stand out as compelling prospects.

    Clearmind Medicine Inc (CMND)

    Clearmind Medicine Inc (NASDAQ: CMND) opened the trading on April 13, 2026, with great promise as it jumped 11.72% to $1.43. During the day, the stock rose to $1.49 and sunk to $1.26. Taking a more long-term approach, CMND posted a 52-week range of $0.59-$52.40.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 39.75%. Meanwhile, its Annual Earning per share during the time was 39.75%.  This publicly-traded company’s shares outstanding now amounts to $2.09 million. The organization now has a market capitalization sitting at $2.98 million.

    China Pharma Holdings Inc (CPHI)

    China Pharma Holdings Inc (AMEX: CPHI) started the day on April 13, 2026, with a price increase of 0.60% at $0.65. During the day, the stock rose to $0.65 and sunk to $0.65. Taking a more long-term approach, CPHI posted a 52-week range of $0.50-$2.60.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 53.14% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 53.14%.  This publicly-traded company’s shares outstanding now amounts to $40.52 million, simultaneously with a float of $18.89 million. The organization now has a market capitalization sitting at $26.33 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term growth profile through pipeline diversification, extending beyond its lead oral therapy into next-generation treatments targeting large-scale cardiovascular markets. This strategic expansion reflects a broader ambition to address both rare inflammatory conditions and widespread chronic diseases.

    Market Momentum

    As of April 13, 2026, CRDL closed at $1.3600, down 1.45%, with trading volume (243,619 shares) well below its average of 589,930 shares—indicating reduced near-term activity and consolidation. With a market cap of $151.885M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.48 continues to suggest significant upside potential, supported by upcoming development milestones.

    Pipeline Expansion: CRD-38

    The company is advancing CRD-38, a subcutaneous therapy designed for heart failure with preserved ejection fraction (HFpEF), a condition affecting approximately half of all heart failure patients globally. Despite its prevalence, there are currently no approved therapies specifically targeting inflammation in HFpEF, creating a substantial unmet need.

    Preclinical Rationale

    Preclinical studies indicate that CRD-38 may reduce fibrosis, prevent cardiac hypertrophy, and protect against functional decline—key drivers of heart failure progression. By addressing both inflammation and structural damage, the therapy has the potential to offer a more comprehensive treatment approach.

    Outlook

    As CRD-38 moves toward clinical development, it represents a significant opportunity to expand Cardiol’s addressable market. Success in this program could position the company as a broader cardiovascular innovator beyond its initial niche focus.

  • China Pharma Holdings Inc. (CPHI) Sees Weekend Surge in Apparent Pump and Dump

    China Pharma Holdings, Inc. (NASDAQ: CPHI) had a lackluster trading day last Friday, experiencing a 1.4% decline with minimal trading activity. However, as the closing bell rang, the after-hours session ushered in an unexpected turn of events. CPHI surged a remarkable 31%, accompanied by a surge in trading volume to 1.6 million shares, a stark contrast from the subdued activity earlier in the day.

    Market Reaction

    The sudden spike in CPHI’s stock price during after-hours trading caught many investors off guard, particularly given the absence of any apparent catalysts. This surge has left some market participants wary, speculating that a subsequent profit-taking dip may be looming on the horizon. Despite this uncertainty, bullish sentiment prevails, with investors eagerly riding the wave of momentum.

    China Pharma Holdings, Inc. is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of products. Their product portfolio encompasses treatments for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products.

    Breaking Down the Spike

    The company’s recent surge in stock price could be attributed to various factors, including speculation surrounding potential developments within its product pipeline or broader market trends. Additionally, the surge highlights the appeal of China-based stocks, particularly during extended trading hours, due to their historically lower trading volumes, which can facilitate significant price movements.

    China Pharma, operating through Helpson, currently operates two production facilities in Haikou, Hainan Province, PRC. These facilities adhere to stringent quality control measures in compliance with the PRC’s Good Manufacturing Practices (GMP) standards and relevant NMPA regulations, ensuring the consistency and quality of their products.

    Looking Ahead

    Looking ahead, the trajectory of CPHI’s stock price remains uncertain, with much hinging on continued trading volume. Despite the current bullish sentiment, investors are advised to exercise caution and closely monitor market developments.

    Overall, China Pharma Holdings, Inc.’s after-hours surge highlights the unpredictability of the stock market and the potential for significant price movements outside of regular trading hours. As investors brace for the week ahead, all eyes remain on CPHI’s trading activity and any forthcoming developments that may impact its stock price.

  • China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) is a biopharmaceutical firm focused on the development, manufacturing, and marketing of products for treating cardiovascular, CNS, and digestive disorders. The products of the company include cerebroprotein hydrolysate for memory decline, gastrodin for loss of concentration, propyl gallate for cerebral thrombosis, bumetanide for edema, and candesartan for hypertension.

    The price of CPHI stock during the regular trading on February 3, 2022, was $0.49 with a 17.2% gain. At last check in the premarket on February 4, 2022, the stock further jumped by 10.1%.

    CPHI: Key Financials

    On November 12, 2021, CPHI released its financial results for the quarter ended September 30, 2021. Some of the key features are discussed below.

    Revenue

    Revenue recorded in Q3 2021 was $2.0 million compared to $2.4 million in the same period of 2020. A decline of 17.6% was observed in the revenue over the period of the year. The decline in the revenue was the result of the extension of the national centralized drug acquisitions scope and the associated price drop. The financial analysts also observed that the company missed the estimated revenue target by $307.2 thousand.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $0.8 million or $0.02 compared to $1.0 million or $0.02 in the same quarter of 2020. The net loss was reduced over the period of the year due to a reduction in selling costs in 2021. The company missed the estimated EPS by $0.04/

    CPHI: CEO Comments

    Speaking at the occasion, CPHI CEO Zhilin Li stated that the company focused on the consistency assessment of its registered products in the quarter. He further added that the company’s lead product Candesartan had passed the consistency assessment test. The company had submitted the application resources to the National Medical Products Administration.

    Conclusion

    CPHI stock is 45% down the past six months due to economic restraints caused as a result of the pandemic. The company’s stock is in a good position in the recent premarket due to uncertain factors as no official statement, SEC filing, or forthcoming event is listed on the company’s website.

  • CPHI Stock Announces Incredible Fiscal Year For 2020

    China Pharma Holdings, Inc. (CPHI) a New York stock exchange-listed pharmaceutical company that produces and advertises a diverse portfolio of products, focuses on diseases with high transmission rates and high mortality rates in China. The company’s efficient business model driven by market demand combined with a very large distribution network across all major cities in China is anticipated to generate massive revenue as the new GMP-certified products release. CPHI stock has also made a subsidiary company known as, Hainan Helpson Medical & Biotechnology Co., located in Haikou city, which specializes in medicine production.

    The company collected net revenue of $10.9M due to foreign trading of COVID-19 testers as market demand for covid related products increased and popped their gross margin from 13.6% in the fiscal year 2019 to 18% in the fiscal year 2020. A Net loss of $2.9 million took place in 2020 against a staggering $20.7 million loss in the fiscal year 2019.

    CPHI Business model variation 

    Ms. Zhilin Li, China Pharma’s Chairman, and CEO stated, “The outbreak of COVID-19 early in this year has created a substantial, negative impact on sales of pharmaceutical companies, including ours. Many people try to avoid going to hospitals for fear of cross-contamination or potential infection” However the company amended its business model to a more consumer-centric approach and started producing products related to Coronavirus which had huge market demand and surged their revenue substantially.

    However, due to unpredicted variation in product demand, market competitiveness; slow-progressing economy, and low levels of RnD, CPHI stock has accumulated a loss of a collective $23M in the past two years and has the company striving for better financial results.

  • Top 15 Healthcare Stocks You Should Add To Your Bucket

    The global generics drug market continues to grow with the increasing demand for more medication. Drug manufacturers are continuously striving to meet the need for more generic drugs. This industry is an opportunity-rich industry. Efficient and inexpensive drugs are often needed. The drug manufacturing industry has seen a huge transformation over the last two decades.

    This industry-main challenge is to provide the drug at lower prices than branded drugs. Drug manufacturers and Specialty Generic Industry will face more pressure in the coming years to lower the prices of drugs.  The industry is expected to grow significantly over the next decade. Check out the leading companies in drug manufacturers- specialty generic industry to see how these are addressing the needs of their customers:

    Sundial Growers Inc. (NASDAQ: SNDL)

    Sundial Growers Inc. (NASDAQ: SNDL) shares were trading down -6.32% at $0.17 at the time of writing on Wednesday. Sundial Growers Inc. (NASDAQ: SNDL) share price went from a low point around $0.17 to briefly over $4.12 in the past 52 weeks, though shares have since pulled back to $0.17. SNDL market cap has remained high, hitting $32.59M at the time of writing, giving it a price-to-sales ratio of more than 0.

    Sundial Growers Inc. (SNDL) has revealed earlier that it has expanded the Palmetto brand presence across Canada. If we look at the recent analyst rating SNDL, CIBC upgraded coverage on SNDL shares with a Neutral rating.

    Teligent Inc. (NASDAQ: TLGT)

    Teligent Inc. (NASDAQ: TLGT) last closed at $1.04, in a 52-week range of $0.65 to $8.00. The Schall Law Firm has earlier revealed that it is investigating claims on behalf of investors in Teligent, Inc. for potential breaches of fiduciary duty on the part of its directors and management. Teligent Inc.’s market cap has remained high, hitting $5.68 Million at the time of writing.

    Zomedica Corp. (AMEX: ZOM)

    Zomedica Corp. (AMEX: ZOM) stock drop by -3.82% to $0.08. Zomedica Corp. (ZOM) revealed that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will start trading under the new name effective on October 5, 2020.

    Aurora Cannabis Inc. (NYSE: ACB)

    Aurora Cannabis Inc. (NYSE: ACB) shares headed rising, higher as much as 6.36%. The most recent rating by Jefferies, on September 21, 2020, is at a Hold. Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of Aurora Cannabis Inc. (ACB) shareholders.

    Tilray Inc. (NASDAQ: TLRY)

    Tilray Inc. (NASDAQ: TLRY) rose 2.96% after gaining more than $0.19 on Wednesday. Tilray Inc. (TLRY) earlier revealed that its wholly-owned subsidiary, High Park Holdings Ltd. has introduced the newest addition to its cannabis-infused edible product line: Chowie Wowie Gummies, which are now available in select provinces across Canada.

    Neos Therapeutics Inc. (NASDAQ: NEOS)

    Neos Therapeutics Inc. (NASDAQ: NEOS) last closed at $0.86, in a 52-week range of $0.45 to $1.98. Neos Therapeutics Inc. (NEOS) has reported that its sales in quarter two reached $13.13 million. However, earnings dropped by 51.17%, resulting in a loss of $2.88 million. In Q1, Neos Therapeutics brought in $14.49 million in sales but lost $5.89 million in earnings.

    Teva Pharmaceutical Industries Limited (NYSE: TEVA)

    Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares headed rising, higher as much as 3.72%. The most recent rating by Barclays, on August 06, 2020, is at an Equal-weight. Pomerantz LLP revealed that a class action lawsuit has been lodged against Teva Pharmaceuticals Industries Limited and certain of its officers.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed falling, lower as much as -2.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. Elanco Animal Health Incorporated (ELAN) has revealed that it has got a notification of an unsolicited ‘mini-tender”‘ offer by TRC Capital Investment Corporation to buy up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock.

    HEXO Corp. (NYSE: HEXO)

    HEXO Corp. (NYSE: HEXO) fall -0.91% after losing more than -$0.01 on Wednesday. HEXO Corp. (HEXO) has earlier disclosed that it has appointed Trent MacDonald to its executive leadership team in the acting role of Chief Financial Officer, effective October 10, 2020. Its market cap has remained high, hitting $365.78 million at the time of writing.

    Bausch Health Companies Inc. (NYSE: BHC)

    Bausch Health Companies Inc. (BHC) last closed at $17.57, in a 52-week range of $11.15 to $31.97. Analysts have a consensus price target of $26.76. Bausch Health Companies Inc. (BHC) and Lomb, its leading global eye health business, along with BHVI, revealed previously that an affiliate of Bausch Health has bought an exclusive license for a myopia control contact lens design developed by BHVI.

    Endo International plc (NASDAQ: ENDP)

    Endo International plc (NASDAQ: ENDP) stock drop by -5.69% to $5.47. The most recent rating by Goldman, on July 27, 2020, is at a Sell. Endo International plc (ENDP) revealed that it has decided to buy all of the outstanding shares of BioSpecifics Technologies Corp. for $88.50 in cash per share or an estimated enterprise value of approximately $540 million at the expected time of deal closure.

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) stock soar by 9.65% to $0.31. China SXT Pharmaceuticals Inc. (SXTC) share has fluctuated between the 52-weeks low of $0.22 and 52-weeks high of $1.56 during the trading session of Wednesday. It has moved up 40.64% from its 52-weeks low and moved down -79.97% from its 52-weeks high.

    Canopy Growth Corporation (NYSE: CGC)

    Canopy Growth Corporation (NYSE: CGC) rose 3.23% after gaining more than $0.61 on Wednesday. Canopy Growth Corporation (CGC) share price went from a low point around $9.00 to briefly over $25.97 in the past 52 weeks, though shares have since pulled back to $19.49. CGC market cap has remained high, hitting $7.24 billion at the time of writing.

    Aphria Inc. (NASDAQ: APHA)

    Aphria Inc. (NASDAQ: APHA) last closed at $4.68, in a 52-week range of $1.95 to $6.44. Aphria Inc. (APHA) has moved up 140.00% from its 52-weeks low and moved down -27.33% from its 52-weeks high. Its market cap has remained high, hitting $1.25 billion at the time of writing.

    China Pharma Holdings Inc. (CPHI)

    China Pharma Holdings Inc. (CPHI) stock soar by 6.86% to $0.50. The most recent rating by Rodman & Renshaw, on January 08, 2010, is at an Mkt outperform. China Pharma Holdings Inc. (CPHI) has moved up 134.13% from its 52-weeks low and moved down -64.53% from its 52-weeks high. Its market cap has remained high, hitting $22.72 million at the time of writing.